Due to increased bone resorption and increased TGF-β release restrained Th1 lineage development, and thus blocking TGF-β signaling together with immune checkpoint inhibitors could have better effects on regression of prostate cancer bone metastases [26]. The gene discussed is TGFB1; the disease is Familial prostate cancer.